
|Videos|April 26, 2022
Updates from Bausch and Lomb: US launch of FDA approved treatment for uveitis, new IOL toric calculator
Author(s)Kassi Filkins
Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Uveitis or retinitis pigmentosa? Ester Carreño, MD, PhD, on mimics
2
EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease
3
MOGENRY earns Japan priority review for inherited retinal dystrophies
4
EURETINA 2026: OCT biomarkers that predict, preempt and pinpoint retinal disease
5














